Peptide Therapies Need Molecular Proof.
The peptide market is exploding — but most therapies lack human clinical trial data.
From BPC-157 to NAD+ precursors to mitochondrial-derived peptides, the biohacking and longevity communities are adopting therapies at scale with limited evidence. Transcriptomics offers a path forward: molecular proof of pathway engagement, measured in real time.
The Peptide Evidence Gap
Most peptide therapies in the wellness and longevity space exist in a regulatory gray zone. They're available through compounding pharmacies and research chemical suppliers, but very few have undergone rigorous human clinical trials.
This creates a fundamental problem: patients and clinicians are making dosing and stacking decisions based on animal data, influencer anecdotes, and forum reports — not human molecular evidence.
Transcriptomics can't replace clinical trials. But it can provide something that doesn't currently exist: objective molecular data on whether a peptide is engaging its intended gene targets in human tissue.
FDA-Approved Peptides
GLP-1 agonists (semaglutide, tirzepatide), insulin, and TRT have extensive human RCT data and well-characterized gene pathways.
Emerging Evidence
NAD+ precursors (NMN, NR) have small human RCTs and well-studied mechanisms, but lack large-scale confirmatory trials.
Animal Data Only
BPC-157, MOTS-c, epitalon, and semax are widely used but have zero or near-zero published human clinical trials. All evidence is preclinical.
Molecular Validation Through Gene Expression
Transcriptomic monitoring doesn't prove a peptide works clinically. But it answers a critical intermediate question: Is this peptide engaging its molecular targets in your body?
Identify Targets
Map the expected gene expression changes for each peptide based on its proposed mechanism. For BPC-157: VEGF, FGF2, eNOS. For NAD+: SIRT1, PGC-1α, NAMPT.
Measure Expression
Run multiplexed transcriptomic panels at baseline and post-therapy to quantify mRNA changes across the target gene set.
Validate Engagement
Determine whether the peptide is producing measurable molecular changes — objective data where none previously existed.
What Transcriptomics Can Monitor
Each peptide category has distinct molecular targets that can be tracked through gene expression. Here's what Biomeme's platform can measure.
Tissue Repair & Healing
BPC-157, TB-500
Proposed mechanisms center on angiogenesis and growth factor modulation. Monitorable gene targets include VEGF (vascular endothelial growth factor), FGF2 (fibroblast growth factor), eNOS (nitric oxide synthesis), and EGF (epidermal growth factor).
NAD+ & Longevity
NMN, NR, Resveratrol
The sirtuin/NAD+ salvage pathway is central to proposed anti-aging mechanisms. Key gene targets: SIRT1 (sirtuin 1), PGC-1α (mitochondrial biogenesis), NAMPT (NAD+ salvage enzyme), and PARP1 (DNA repair).
Mitochondrial Peptides
MOTS-c, Humanin, SS-31
Mitochondrial-derived peptides activate metabolic stress pathways. Monitorable targets include AMPK signaling, NRF2 (antioxidant response), GLUT4 (glucose uptake), and folate-methionine cycle enzymes.
Hormonal & Neuropeptides
TRT, Semax, Selank, Kisspeptin
Hormone and neuropeptide therapies modulate receptor-mediated transcription. Targets include androgen receptor (AR) responsive genes, BDNF (neuroplasticity), FST/MSTN (follistatin/myostatin axis), and CYP19A1 (aromatase).
Want to see how individual peptides score across evidence dimensions? Explore the Peptide Evidence Score →
"For most peptides being used in the wellness space, we have preclinical mechanisms and clinical anecdotes — but very little human molecular data in between. That gap is where transcriptomics can add real value."
From Animal Data to Human Molecular Evidence
Biomeme's multiplexed transcriptomic platform is uniquely positioned to generate the molecular data that the peptide space desperately needs.
Enough to cover multiple peptide pathway panels in a single test.
Individual longitudinal tracking — your gene expression changes over time.
Clinical-grade results through One Health Labs — not a research toy.
Curious how we measure this?
Learn about the foundational science of Transcriptomics and how Biomeme brings molecular profiling to the point of need.
Ready to Learn More?
Explore how Biomeme's capabilities are being deployed across the Wellness landscape.